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Abstract 
Objective: To compare fecal transplant and vancomycin in the treatment of recurrent 
clostridium difficile to determine which has the higher cure rate. Design: Systematic 
literature review. Methods: Pubmed, Google Scholar, and TRIP database using the 
search terms “recurrent clostridium difficile.” Filters were implemented in the Pubmed 
database including: randomized control trials, English, and published in the past 5 
years. Records were screened for RCT with fecal transplant and full-text. Results: van 
Nood et al. revealed an initial cure rate of 81% for the infusion group, and a re-treated 
cure rate of 94%, compared to the vancomycin alone group of 31% cure rate and the 
vancomycin plus bowel lavage group of 23% cure rate. Cammarota et al. determined an 
initial cure rate of 65% for the infusion group, and a re-treated cure rate of 90%, 
compared to the vancomycin only group of 26% cure rate. Conclusion:  An initial 
abbreviated dose of vancomycin at the start of fecal transplant has a significantly higher 





Clostridium difficile (C. difficile), a gram-positive, anaerobic bacillus bacterium, is 
spread via the fecal-oral route, and is known for it’s colonization of the gastrointestinal 
tract, commonly after a regimen of antibiotic therapy has been used, altering the normal 
gut flora of the patient.1,2,3 In the United States, C. difficile infection is the most common 
healthcare associated infection, and is increasing in both frequency and severity of 
infection.3,2 High-risk populations include 65 years or older, less than 1 year old with 
underlying condition, male gender, increased hospitalization time, and recent 
antimicrobial therapy.3 Known antibiotics associated with the development of C. difficile 
include fluoroquinolones, clindamycin, penicillins, and cephalosporins.4 According to 
Barbut et al, C. difficile infections may cost up to $3.2 billion per year, along with 
causing an estimated 15,000 – 20,000 deaths annually in the United States alone.5  
There are seven stages of C. diff infection, including: Carrier stage, C. difficile- 
associated diarrhea, C. difficile-associated Colitis, Pseudomembranous Colitis, 
Fulminant Colitis, Recurrent Clostridium difficile infection (CDI), and Extracolonic 
Infections.3 The studies included in this systematic literature review are looking at 
recurrent Clostridium difficile primarily, which involves the complete resolution of 
symptoms associated with the initial occurrence of C. difficile after therapy, followed by 
a relapse of symptoms and C. difficile infection.4 In approximately 10 – 25% of patients 
who have completed C. difficile therapy, recurrence will occur.4 Symptoms associated 
with recurrent C. difficile include the cardinal symptom of watery diarrhea with at least 3 
stools within 24 hours, abdominal pain, low-grade fever, nausea, and anorexia.4 
Diagnosis of CDI infection is primarily clinical, with a history including recent 
antimicrobial use and diarrhea.3 Laboratory tests are performed on unformed stool 
samples.3The best sample for diagnosis consists of watery or loose stool, as fresh as 
possible. Culture may be performed, but is not routinely done due to the cost and 
clinician experience needed. If culture is performed, it is recommended to do so with the 
assistance of infectious disease specialist and/or gastroenterology specialists. There is 
a variety of toxin assays that may be used for the detection of Clostridium difficile, 
including cell culture neutralization assay, which is highly sensitive and specific, but 
time-consuming and labor-intensive. Immunoassay detects both toxins A and B, utilizing 
methods such as enzyme immunoassay and immunochromatography. Nucleic Acid 
Amplication, with sensitivity of 90-100% and specificity of 94-100%, are the most recent 
methods, able to identify genes of Clostridium difficile. Latex agglutination assay detects 
glutamate dehydrogenase, but is not used routinely. If there are normal stool laboratory 
test results with high suspicion, then sigmoidoscopy and colonoscopy may be used for 
diagnosis.3 
Initial treatment for a patient with C. difficile begins with the cessation of any 
current antibiotics that the patient may be taking, if possible.1 After stopping the 
offending medication, current treatment options for recurrent Clostridium difficile include 
primarily a course of vancomycin or fixoxamycin; however, fecal transplant is now 
becoming a viable option. Standard vancomycin for the treatment of Clostridium difficile 
is 500 mg PO QID.3 According to Goudarzi et al., approximately 25% of patients with C. 
difficile who have been treated with either metronidazole or vancomycin experience 
recurrent symptoms, within 4 weeks of completing therapy.3  
The basis of fecal microbiota transplant involves the restoration and re-
colonization of healthy, normal gut flora in the affected gastrointestinal tract due to C. 
difficile invasion or irritable bowel disease, along with other various causes of altered 
gut flora. Fecal transplant implements a donor that undergoes extensive screening and 
testing. The donors are screened via a questionnaire on such things as medical history, 
lifestyle habits, antibiotic use in the past 6 months, intestinal diseases and/or symptoms. 
The donor stool is screened for C. difficile enteric bacteria, protozoa, helminthes, as well 
as drug resistant bacteria. The donors blood is also tested for hepatitis A, B and C, HIV-
1 and HIV-2 antibodies, Epstein-Barr virus, Treponema pallidm, Strongyloides 
stercoralis and Entamoeba histolytica. First the feces is collected from the donors on the 
day of infusion and then diluted with 500 mL of sterile saline (0.9%) and blended. Finally 
the supernatant was strained and stored in a sterile container until infusion. The feces 
can be given to the patient via nasogastric tube, colonoscopy, enema, and via 
capsulated pill. Of these routes, for patients with recurrent C. difficile, colonoscopic fecal 
microbial transplant is superior to nasogastric fecal transplant in regards to the cure rate 
of this infection.6 Diarrhea, constipation, abdominal cramping, gurgling, and gas are the 
adverse effects that have been present after a fecal microbial transplant, although 
considered brief and minor occurances.6  
Infection control is an important aspect throughout the treatment of a CDI 
infection. One of the most important aspects of CDI prevention is hand washing with 
both soap and water, which is more effective compared to an alcohol based solution.3,1 
Appropriate contact precaution including wearing gloves and gowns when working with 





In patients over 18 years old who have developed recurrent Clostridium difficile, is fecal 
transplantation compared to vancomycin more efficacious in the treatment of recurrent 




In October of 2015 the PubMed 
database was searched using the terms 
recurrent clostridum difficile, which 
yielded 669 results initially. Searches of 
Google Scholar and TRIP databases 
produced no additional articles. These 
results were then limited to English only 
and randomized control trials within the 
past 5 years. This reduced the number 
of results to 10. Next these trials were 
reviewed and only those that involved 
fecal microbiota transplant were chosen. 
There were a total of three trials that met 
these criteria. Of the three trials only two 
looked at fecal microbiota transplant v.s. 
vancomycin. The third trial was a pilot 
RCT assessing administration routes for 
fecal microbiota transplant and was 
eliminated. The two articles meeting 
these criteria were Duodenal Infusion of 
Donor Feces for Recurrent Closridium 
difficile. Van Nood et al and Randomised 
clinical trial: faecal microbiota transplantation by 
colonoscopy vs. vancomycin for the treatment of 
recurrent Clostridium difficile infection. 





Study #1  




To determine if fecal transplant with vancomycin for the treatment options for recurrent 
Clostridium difficile is more effective compared to vancomycin alone or vancomycin with 
bowel lavage.  
Figure 1. PRISMA Flow Diagram. 
Study Design 
In this open label, randomized controlled trial, 43 patients were divided into three 
treatment groups: initial abbreviated vancomycin regimen with bowel lavage and donor 
feces, standard vancomycin regimen with bowel lavage, and standard vancomycin 
regimen. The Table 1 demonstrates the study population via inclusion and exclusion 
criteria. The feces donor criteria are outlined in Table 2 that was given to the fecal 
transplant group via nasoduodenal tube. If the fecal transplant group required a second 




Table 1. Patient Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
≥ 18 years old 
Life expectancy ≥ 3 months 
Relapse of C. difficile infection 
after at least one course of 
adequate antibiotic therapy 
Prolonged immunodeficiency due to recent 
chemotherapy 
HIV infection with a CD4 count < 240 
Prolonged use of prednisolone at a dose of ≥ 60 
mg/day 
Pregnancy 
Use of antibiotics other than for treatment of C. 
difficile infection at baseline 
Admission to an intensive care unit 
Need for vasopressor medication 
 
Table 2. Feces Donor Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
<60 years of age History of parasites, C. difficile, and enteropathogenic bacteria, 
HIV, Human T-cell lymphotropic virus types 1 and 2, Hepatitis A, 




The infusion group initially had an 81% (13/16 patients) cure rate, that increased 
to 94% (15/16 patients) after 3 more participants were re-treated with an additional 
infusion from a different donor. The vancomycin alone group had a 31% (4/13 patients) 
cure rate. The vancomycin plus bowel prep group had a 23% (3/13 patients) cure rate. 
Adverse events reported immediately after infusion were 94% of patients reported 
diarrhea, 31% cramping, and 19% belching. All of the effects were self-limiting and 
resolved within 3 hours of presentation. During the follow up visit 19% of patients 
reported constipation. No adverse events were reported in the other two groups. This 
study was terminated early by the monitoring board due to a high number of relapse in 
both of the vacomycin groups. 
 
Number Needed to Treat (NNT): 1.58. We chose the use the vancomycin alone group 
as the control to determine the number needed to treat compared to the infusion group. 
The NNT may be interpreted as 1.58 patients must be treated over a period of 1 year to 
prevent one recurrence of CDI.  
 
Study Critique 
There was no comparison between the standard vancomycin regimen with bowel 
lavage to the standard vancomycin regimen groups. Both groups were compared to the 
initial vancomycin regimen with bowel lavage and donor feces, but not to each other. 
The small population size is also a disadvantage of this study resulting in a possible 
type II error or failing to show statistical significance when there is actually a difference 
between the two study groups. This study also terminated early due to high recurrence 
rates of the vancomycin group..For patients that were in the vancomycin groups, if their 
therapy failed, they were able to choose to have the donor feces given off protocol, 
which adds confounding variables to this study.  
 
Study #2 
Randomized clinical trial: faecal microbiota transplantation by colonoscopy vs. 
vancomycin for the treatment of recurrent Clostridium difficile infection. Cammarota et 
al8 
Study Objective  
To investigate if fecal transplantation is more effective at treating recurrent Clostridium 
difficile compared to vancomycin standard therapy.  
 
Study Design 
Open label, blocked randomized clinical trial comparing faecal microbiota 
transplantation with vancomycin treatment to vancomycin only treatment. Blocked 
randomized clinical trial refers to the addition of an external person, which is not 
involved in the study, and a random number generator software that uses random 
subgroup “block” sizes of 6 in addition to a ratio, which reduces variability within groups 
and reduces likelihood of confounding8. All patients who met the inclusion and exclusion 
criteria as outlined in Table 3, began the study with a three-day abbreviated treatment of 
vancomycin (125 mg by month four times a day). At day 2 and 3, the fecal transplant 
group also had a bowel lavage.  At day four, they then either continued with the 
vancomycin regimen, or stopped the vancomycin and began the first faecal infusion 
from a fecal donor that met the inclusion and exclusion criteria as outlined in Table 4. 
The vancomycin only treatment group continued with the 125 mg until day 11, when 
they switched to vancomycin pulse regimen (125-500 mg/day every 2-3 days). Patients 
that were diagnosed with pseudomembranous colitis were given a fecal infusion every 3 
days, and patients in the fecal transplant group who relapsed after the first fecal 
transplant, were given a second fecal transplant by a different donor within 1 week.  
 
 
 Table 3. Patient Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
≥18 years of age 
Life expectancy ≥ 3 
months 
Recurrence of C. difficile 
after one or more courses 
of specific antibiotic 
therapy  
Believed able to undergo 
colonoscopy 
Prolonged immunodeficiency due to recent chemotherapy 
HIV infection 
Prolonged use of steroids 
Pregnancy 
Use of antibiotics other than metronidazole, vancomycin 
or fidaxomicin at baseline 
Admission to an intensive care unit 
Requirement for vasoactive drugs 
Other infectious causes of diarrhea 
 
Table 4. Feces Donor Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
Healthy 
volunteers < 50 




Antibiotics taken within the last 6 months 
Exhibited significant intestinal symptoms of other intestinal 
diseases 
Lifestyle associated with increased risk for contracting infections 
Recent (≤3 month) travels in tropical areas 
New sexual relationship in the last 6 months 
Recent needlestick accident 
Previous reception of blood products 
Body tattoos 
Gastrointestinal diseases or complaints 
Family history of gastrointestinal cancer or inflammatory bowel 
disease 
Systemic diseases such as diabetes or neurological disorder 









Table 5. Overview of Studies 
 
van Nood et al. 
Cammarota et al. 
Population Referring hospitals in collaboration with the 
Academic Medical Center in Amsterdam  
The A. Gemelli University 
Hospital in Rome.  
Primary 
Interest 
To compare fecal transplant with an 
abbreviated vancomycin treatment to 
vancomycin standard therapy and vancomycin 
with bowel lavage in the treatment of recurrent 
Clostridium difficile 
To compare fecal 
transplant with an 
abbreviated vancomycin 
treatment to vancomycin 
standard treatment in the 













Patients, N 16 13 13 20 19 
Gender 50% F, 
50% M 
54% F, 46% M 23% F, 77% M 60% F, 
40% M 
58% F, 42% 
M 
Average Age 73 +/- 13 66 +/- 14 69 +/- 16 71 75 
Randomized Yes Yes 
Analysis  Intention to treat Intention to treat 
Definition of 
Cure 
10 weeks of no diarrhea 10 weeks of no diarrhea 
The infusion group initially had a 65% (13/20 patients) cure rate that increased to 
90% (18/20 patients) after multiple infusions. Two of the patients in this group died 
before the end of the study due to C. diff complications. The vancomycin only treatment 
was 26% effective with 5 of the 19 cured after treatment. Two of the patients in this 
group died before the end of the study due to C. diff complications as well. Overall 
intention to treat analysis of the transplant group compared to the vancomycin group 
demonstrated that the infusion group was superior and statistically significant with 
p<0.0001 (90% vs. 26%). After one year an interim analysis was done revealing a  
significantly higher efficacy than vancomycin and the study was stopped with a total of 
only 39 enrolled patients. Immediately after infusion 94% experienced diarrhea and 60% 
bloating/cramping, all symptoms resolved within 12 hrs. There were no adverse events 
reported in the vancomycin group. 
 
Number Needed to Treat (NNT): 1.57. We used the vancomycin only treatment group 
and the faecal microbiota transplantation with vancomycin treatment group to determine 
the NNT. The NNT may be interpreted as 1.57 patients must be treated over a period of 
1 year to prevent recurrence of CDI.  
 
Study Critique 
Patients involved in infusion group were able to repeat the fecal transplant as many 
times as needed to improve the cure rate. For the patients with pseudomembranous 
colitis, the fecal transplant frequency increased to an infusion every 3 days until cured, 
although the study does not address the maximum time or number of infusions that 
were done before the patients were cured. The cost and risk of complications for the 
treatment groups was not discussed either. The vancomycin group may or may not 
have had patients with pseudomembranous colitis, since this was not determined via 
colonscopy as it was for the fecal transplant group. The small population size is a 
disadvantage of this study. The early termination of the study caused the study to fall 





The mainstay of treatment for C.difficile infection since the 1970’s has been 
metronidazole and oral vancomycin with the addition of findaxomicin in 2011.9 Phase 
three clinical trials showed a risk of recurrent infection around 25% with vancomycin.10 
Given the relatively high mortality, morbidity, and recurrence rates of this infection the 
investigation of other viable treatment options is warranted. 
 
An overview of these two studies may provide some insight into the efficacy of this 
unusual treatment. Both the Els van Nood et al and the Cammarota et al studies were 
Blinding Preceptors and participants were not blinded, 
but the assessors of “cured” were blinded. 
No 
open-label randomized trials, although the Cammarota et al study did not assign a 
control group. The recipient group inclusion/exclusion criteria for the two studies were 
nearly identical, although the donor 
criteria differed heavily (Tables 1 and 
3). The inclusion/exclusion criteria for 
the donors were very different and 
are outlined in tables 2 and 4. The 
treatment protocols were very similar 
but varied slightly between studies. 
For obvious reasons, neither study 
could blind the patients or the 
treating clinicians although van Nood 
et al did use a masked committee to 
determine which patients were 
cured. Cammarota et al study used a lower 125mg dose of vancomycin compared to 
the 500mg dose used by Els van Nood et al study. Both studies started the infusion 
groups off with an abbreviated 3-5 day course of vancomycin. The delivery methods 
differed between the studies, Els van Nood et al used nasoduodenal infusion where 
Cammarota used colonoscopy. Both studies used 10 weeks as the primary end point for 
cure of infection without relapse. The two studies did their statistical analyses on an 
intention to treat basis, Cammarota et al did elect to also analyze their data on a per 
protocol model as well. According to both of these studies, the difference between the 
fecal transplant with the vancomycin and the vancomycin only is statistically significant 
with P<0.001 and P<0.0001 for Els van Nood et al and Cammarota et al respectively. 
We independently calculated the number needed to treat values for both studies to be 
1.58 for Els van Nood et al and 1.57 for Cammaroda et al. The two studies we reviewed 
were very similar with regard to statistical power, design, cure rates, and number 
needed to treat. They did differ in delivery methods, dosing, and in regard to donor 
selection.  Figure 2 provides a visual comparison between the percentage of patients in 
these two studies who were “cured” for both the fecal transplant with abbreviated 









The differences between these studies may have impacted the data - such as the 
delivery route of nasoduodenal tube versus colonoscopy. Currently there are some 
Figure 2. Percentage cured at the end of treatment, 
comparing the vancomycin group to the fecal 
transplant group between the two research papers.  
 
randomized controlled trials investigating the most efficient route for administration and 
as soon as the best route is identified future studies may be able to utilize similar routes 
and reduce the error that this may produce in determining efficacy of fecal transplant. 
The screening of the donors also differed in the criteria that were used to determine the 
eligibility of the donor. A standard protocol for donor selection would help reduce bias as 
well as and help to protect against the transmission of pathogens.  These two studies 
combined included a total of 68 participants for both the infusion and vancomycin 
groups. Overall these two studies suggest strongly that fecal microbiota transplant is 
superior to vancomycin at treating recurrent C. difficile infection. Given the limited 
sample size of these two studies and the potential for the transmission of pathogens 
from donor to recipients we feel that more larger scale RCT are warranted before this 
very promising treatment option is accepted as a safe effective alternative to the current 
standard of antibiotic therapy.  
 
Potential harms of fecal transplant include the inherent risks from the different delivery 
methods such as trauma from the insertion of the nasogastric tube or the endoscope for 
the colonoscopy. There is the possibility of transmission of infectious diseases but there 
has yet to be any documented cases of this so far.  
 
The risk associated with oral vancomycin include nephrotoxicity, hypokalemia, fever, 
rash (Stevens-Johnson syndrome), ototoxicity, anaphylaxis, and superinfection.   
 
Both of these studies compare standard vancomycin treatment to an abbreviated 
vancomycin in addition to fecal transplant. It will be interesting to see a study that 
compares an abbreviated course of vancomycin in addition to fecal transplant to a 
stand-alone fecal transplant therapy to further differentiate between the efficacy of the 
two treatments. Another area of interest for future studies includes using intensive care 
unit patients that were excluded from these two studies, to help determine the 
effectiveness of vancomycin versus fecal transplant, since these patients may be more 




Dr. Erika Kancler and Caroline Shubert at James Madison University.  
 
Great job!  
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